Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

68.11 USD +2.59 (+3.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 715,042
Open 65.78
Bid (Size) 68.11 (73)
Ask (Size) 68.12 (1)
Prev. Close 65.52
Today's Range 65.11 - 69.44
52wk Range 25.49 - 73.00
Shares Outstanding 80,496,771
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
From GlobeNewswire News Releases
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases

Performance

YTD
+24.77%
+24.77%
1 Month
+5.04%
+5.04%
3 Month
+54.06%
+54.06%
6 Month
+49.10%
+49.10%
1 Year
+132.46%
+132.46%

More News

Read More
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
From GlobeNewswire News Releases
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
From Business Wire News Releases
Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
From GlobeNewswire News Releases
Unusual Options Activity Insight: Apellis Pharmaceuticals
Tags APLS Market News Options
From Benzinga
Analyst Ratings For Apellis Pharmaceuticals
Tags Analyst Ratings BZI/AAR Benzinga
From Benzinga
10 Biggest Price Target Changes For Thursday
Tags Building Products Analyst Ratings Price Target
From Benzinga
Noteworthy Wednesday Option Activity: CLW, LULU, APLS
Tags Stocks
From Market News Video
10 Biggest Price Target Changes For Friday
Tags APLS SEDG Pre/Market Outlook
From Benzinga
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
Tags News Gene Editing Health Care
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.